Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

PEACH Trial: Prescribed Exercise After Chemotherapy (PEACH)

12 de agosto de 2011 actualizado por: University of Dublin, Trinity College

Individually Prescribed Exercise Versus Usual Care in a Heterogeneous Cancer Survivor Population: A Pragmatic Randomized Controlled Trial

Many cancer survivors suffer symptoms such as fatigue and dyspnea which may persist for years or months after their chemotherapy has finished. Despite the known benefits of exercise and its potential to address many of the symptoms after cancer, the type of practical exercise programme which best suits this population is not known.

Many exercise programmes performed in cancer survivors take place over many weeks or months and include people with specific types of cancer. Such programmes may therefore not be suitable for the majority of cancer survivors and would pose serious practical difficulties with high drop-out rates and expensive resource consumption if they were extended into clinical practice.

We propose to run an 8-week exercise intervention in a mixed cancer population.

Hypothesis: A brief, individually tailored 8-week intervention will increase fitness and improve other physical symptoms in a mixed cancer survivor population after chemotherapy.

Descripción general del estudio

Estado

Terminado

Condiciones

Intervención / Tratamiento

Descripción detallada

Background: Many cancer survivors suffer a range of physical and psychological symptoms with may persist for years or months after treatment finishes. Despite the known benefits of exercise and its potential to address many of these adverse effects of treatment, the role of exercise as well as its optimum duration, frequency, and intensity in this population has yet to be fully elucidated. Many cancer rehabilitation programmes presented in the literature are very long, have tight eligibility criteria and are not likely to be practical in the majority of cancer survivors. We plan to investigate a novel brief 8-week intervention which aims to increase physical fitness, and address other physical symptoms in a heterogeneous cancer survivor population.

Methods/design: Approximately 60 cancer survivors 2-6 months after completion of chemotherapy, usually adjuvant, with curative intent will be recruited through oncology clinics in a single institution and randomised to usual care or an exercise intervention. The exercise intervention consists of two specifically tailored, supervised, moderate intensity aerobic exercise sessions per week for 8 weeks. All participants will be assessed at baseline (0 weeks), post intervention (8 weeks), and at 3-month follow-up. The primary outcome measure is fitness, and secondary patient-related outcome measures include fatigue, quality of life, and morphological outcomes. A further secondary outcome is process evaluation including adherence to and compliance with the exercise program.

Discussion: This study will provide valuable information about the physical outcomes of this 8-week supervised aerobic programme. Additional process information and economic evaluation will inform the feasibility of implementing this program in a heterogeneous population after chemotherapy treatment with curative intent.

Tipo de estudio

Intervencionista

Inscripción (Actual)

43

Fase

  • Fase 3

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

      • Dublin, Irlanda, 8
        • Medical Oncology Department, St. James's Hospital

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

21 años a 70 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Diagnosis of solid tumour and completion of adjuvant chemotherapy (and/or radiotherapy) with curative intent within the preceding 2-6 months. (Patients who have received neoadjuvant chemotherapy or chemoradiotherapy followed by surgery will also be eligible. In addition, patients continuing onto adjuvant hormone therapy and anti-Her2 directed therapy are eligible).
  • Ability to understand English
  • Willing to be randomised
  • Medical clearance to exercise
  • Age 21-69
  • Fitness level average, fair or poor according to certain pre-determined cut-off points for age and gender(Fletcher et al., 2001)
  • Willing and able to attend supervised exercise sessions twice weekly for a period of 8 weeks, with an intention of achieving > 90% attendance
  • LVEF > 50% and not < 20% worse than baseline in applicable patients

Exclusion Criteria:

  • Evidence of active cancer
  • Chronic medical and orthopaedic conditions that would preclude exercise (eg uncontrolled congestive heart failure or angina, recent MI, breathing difficulties requiring oxygen use or hospitalization)
  • On beta-blocker medication
  • Prior history of another cancer in previous 5 years (exception: non-melanoma skin cancer and non-invasive cancer of the cervix)
  • Confirmed pregnancy
  • Dementia or psychiatric illness that would preclude ability to participate in study
  • Incomplete haematological recovery after chemotherapy (WCC< 3, Hb < 10 or Platelets < 100)
  • BMI > 35
  • LVEF post chemotherapy < 50% or > 20% deterioration of baseline pre-systemic treatment. LVEF criteria are applicable in patients who have received chemotherapy deemed in normal clinical practice to have a potential effect LVEF and in whom the LVEF will have been measured before systemic treatment and at end of chemotherapy

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Comparador activo: Exercise Programme
This will consist of an 8-week exercise programme, performed twice per week.
Moderate intensity exercise
Comparador de placebos: Usual Care
Standard practice including opportunistic exercise advice and patients' self-directed physical activity
Moderate intensity exercise

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Periodo de tiempo
Modified Bruce Treadmill Test (Fitness)
Periodo de tiempo: 0, 8 weeks, 3 months
0, 8 weeks, 3 months

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
FACT-G scale (Quality of life-overall)
Periodo de tiempo: 0, 8 weeks, 3 months
0, 8 weeks, 3 months
FACT-F (Fatigue)
Periodo de tiempo: 0, 8 weeks, 3 months
0, 8 weeks, 3 months
RT3 Accelerometry (Activity level)
Periodo de tiempo: 0, 8 weeks, 3 months
0, 8 weeks, 3 months
Tanita Body Fat Assessment (% fat)
Periodo de tiempo: 0, 8 weeks, 3 months
0, 8 weeks, 3 months
SF-36v2 (Quality of life-functional aspects)
Periodo de tiempo: 0, 8 weeks and 3 months
0, 8 weeks and 3 months

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Investigador principal: Dearbhaile O' Donnell, MD, St. James's Hospital, Dublin, Ireland
  • Investigador principal: Juliette Hussey, PhD, Trinity College Dublin, Ireland
  • Investigador principal: Julie M Walsh, MSc, University of Dublin, Trinity College

Publicaciones y enlaces útiles

La persona responsable de ingresar información sobre el estudio proporciona voluntariamente estas publicaciones. Estos pueden ser sobre cualquier cosa relacionada con el estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de enero de 2010

Finalización primaria (Actual)

1 de agosto de 2011

Finalización del estudio (Actual)

1 de agosto de 2011

Fechas de registro del estudio

Enviado por primera vez

11 de diciembre de 2009

Primero enviado que cumplió con los criterios de control de calidad

11 de diciembre de 2009

Publicado por primera vez (Estimar)

14 de diciembre de 2009

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

15 de agosto de 2011

Última actualización enviada que cumplió con los criterios de control de calidad

12 de agosto de 2011

Última verificación

1 de noviembre de 2009

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • CTPF/2008/12

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir